spec sheet6 rows
Tolibut is a Russian GABA analogue; phenibut with a methyl group where phenibut has plain phenyl, and baclofen with that methyl in place of baclofen's chlorine [6]. It has been described as analgesic, tranquilising and neuroprotective, and essentially all of that rests on Soviet-era rodent work [2][3]. It is not clear that it was ever approved or used medically, even in Russia.
- Dose-dependent analgesia in rodents, including potentiation of an opioid [2]
- Neuroprotective on a maximum-electroshock model, shortening coma and speeding recovery of movement [1]
- Unknown in humans. In rats it deepened and prolonged anaesthesia [2], so additive CNS depression is the predictable risk
Mechanism
Structurally tolibut is beta-(4-methylphenyl)-, so the assumed mechanism is the one its relatives use: GABA-B activity, as in baclofen and phenibut [6]. ⚠️ That assumption has not been demonstrated by binding. The nearest evidence is a 2024 computational study that docked R- analogues into the extracellular domain of the human GABA-B receptor and modelled their binding energies; docking is a prediction, not a measurement [5]. Separately, a 1992 electrophysiology paper reported that tolibut, alongside several unrelated analgesics, blocked the inward voltage-gated sodium current in neurons, and proposed that as a shared analgesic mechanism at the neuronal level [4]. The two accounts have never been reconciled.
receptor fingerprint
-B receptorproposed agonist; inferred from the baclofen and phenibut scaffold and supported only by docking, never by a measured binding constant
Voltage-gated sodium channelreported block of the inward electrosensitive sodium current in neurons, proposed as a shared analgesic mechanism
Safetyrisks and cautions, not medical advice
HUMAN SAFETY DATA: none. No trial, no case series, no post-marketing surveillance, and no published human pharmacokinetics; everything below is rodent. Tolibut is a close structural relative of phenibut, and phenibut's defining hazard is tolerance and a severe withdrawal syndrome on regular use. Nothing rules that out here and nothing has looked for it, so treat the absence of reports as absence of study rather than as evidence of safety. In rats it deepened and prolonged anaesthesia [2], which is the kind of interaction that matters if it is combined with alcohol, benzodiazepines or any other CNS depressant.
History
The racemate was synthesised and resolved into its enantiomers in 1978, and the absolute configuration determined; the R(+) enantiomer was 14 to 27 times more active than S(-) in CNS screening, and about twice as active as the racemate [3]. Soviet pharmacology through the 1980s characterised it mainly as an analgesic, dose-dependently blunting the perceptive, emotional and autonomic components of pain in mice and rats and potentiating the opioid promedol [2]. Interest since has been almost entirely synthetic rather than clinical: tolibut recurs as a target molecule in methodology papers on making chiral GABA derivatives [5][6][7].
Subjective profileweighing the evidence above
Interesting as chemistry, thin as a supplement. The one study that put it directly against phenibut found phenibut the stronger neuroprotectant, and tolibut antiamnestic on only one of two amnesia models [1]. There is no human data at all; if you want the effect this promises, the honest comparison is a drug that has actually been studied in people.
Resources
This entry is here for reference.
Research
- 1978first cited3-(p-tolyl)-4-aminobutanoic acid synthesis, resolution into enantiomers and pharmacological act…
- 2026most recentAsymmetric synthesis of enantioenriched lactams from cyclic ketones via Beckmann rearrangement.
- 1.Comparison of Nootropic and Neuroprotective Features of Aryl-Substituted Analogs of Gamma-Aminobutyric Acid.
- 2.[The spectrum of analgesic activity of baclofen and tolibut].
- 3.3-(p-tolyl)-4-aminobutanoic acid synthesis, resolution into enantiomers and pharmacological activity.
- 4.[A hypothesis of the possible mechanism of the action of analgesic agents at the neuronal level].
- 5.Synthesis of R-GABA Derivatives via Pd(II) Catalyzed Enantioselective C(sp(3))-H Arylation and Virtual Validation with GABA(B1) Receptor for Potential leads.
- 6.Asymmetric Michael Addition in Synthesis of β-Substituted GABA Derivatives.
- 7.Asymmetric synthesis of enantioenriched lactams from cyclic ketones via Beckmann rearrangement.
7 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
Limitations of the evidence
- No human data of any kind: no trial, no case report, no pharmacokinetics
- Head to head, phenibut was the stronger neuroprotectant and tolibut was antiamnestic on only one of two amnesia models [1]
- GABA-B activity is inferred from structure and docking, never measured [5]
- Almost all pharmacology is Soviet-era and much of it published only in Russian [2][4]
Adverse effects
- Unknown in humans. In rats it deepened and prolonged anaesthesia [2], so additive CNS depression is the predictable risk
Notes and cautions
- The R(+) enantiomer carries essentially all the activity; most material is racemic [3]